Irinotecan Plus Raltitrexed in Treating Patients With Refractory Solid Tumors
Status:
Completed
Trial end date:
2001-01-01
Target enrollment:
Participant gender:
Summary
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so
they stop growing or die. Combining more than one drug may kill more tumor cells.
PURPOSE: Phase I trial to study the effectiveness of irinotecan plus raltitrexed in treating
patients who have refractory solid tumors that have not responded to previous therapy.